Welcome to our dedicated page for Cytosorbents news (Ticker: $CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytosorbents's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytosorbents's position in the market.
CytoSorbents reported unaudited financial results for the first quarter of 2024, showcasing a robust 14% increase in product sales year over year and a 22% sequential increase. The company's product gross margins improved to 76%, marking the highest quarter for core CytoSorb sales in nearly 3 years. Additionally, the STAR-T data presented at AATS supported a favorable benefit-to-risk profile of DrugSorb-ATR in CABG patients. CytoSorbents is on track for FDA De Novo and Health Canada submissions for DrugSorb-ATR in Q3 2024.
CytoSorbents announced a virtual Key Opinion Leader and Analyst-Investor Day to discuss the STAR-T pivotal trial results and real-world experience with antithrombotic drug removal in Europe. The event will focus on severe perioperative bleeding in heart surgery patients on blood thinners, including Brilinta®. Experts will present key findings from the STAR-T trial and real-world data in the pre-specified CABG population, addressing the challenges of coronary artery disease and heart attacks globally.